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Abstract 
Most drug delivery systems as treatment modalities for osteomyelitis have not been 
evaluated for resistant infections. Tigecycline (TG) is an antimicrobial agent that could 
be used in the treatment of multi-drug-resistant orthopedic infections. The objective of 
this in vitro study has been to determine what dosage of TG causes changes in the 
morphology and number of osteoblasts. We have also investigated whether 
nanoparticulate tigecycline-loaded calcium-phosphate/poly(DL-lactide-co-glycolide) is 
biocompatible and whether it could release bioactive TG in a controlled manner during 
the observation time. The cytotoxicity was tested by analyzing the release of lactate 
dehydrogenase from dead osteoblasts to the medium. Staphylococcus aureus was used 
to verify the antibacterial effect of the multifunctional drug delivery system. At 
concentrations as achieved by local application, TG caused high toxic effect and 
impaired the normal osteoblastic morphology. The nanoparticulate multifunctional drug 
delivery system showed good compatibility and antibacterial effect during the 
observation time and thus appears to be suitable for the treatment of osteomyelitis 
caused by multi-drug-resistant microbes. 
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 1. Introduction 
The septic disease osteomyelitis represents the worst complication in orthopedic surgery 
and traumatology. It is difficult to ensure effective bone transplantation and to treat the 
infection at the same time. The systemic administration of antibiotics cannot provide 
sufficient local drug concentration and long-term administration may cause side-effects. 
In patients with bone defects, such treatments must have two stages, i.e. the control of 
the infection, as the first, and bone grafting as the second stage. In recent years, diverse 
antibiotic delivery systems have been developed as treatment modalities in infectious 
bone injuries or chronic osteomyelitis. Their advantage rests in the possibility to achieve 
a high local antibiotic concentration without exposing the patient to systemic toxic 
levels [1-6]. Most antibiotic delivery systems have not been evaluated for unusual or 
resistant infections and their impact remains limited in the rapidly changing field of 
orthopedic microorganisms. Finally, once drug elution has tapered off, the carrier 
becomes another foreign body that fosters bacterial colonization.  
Multifunctional drug delivery systems (MDDS) are designed with the idea of ensuring a 
slow release of the drug, the elimination of the drug carrier and regeneration of the 
place at which the implant was placed. Poly(d,l-lactide-co-glycolide) (PLGA) is a 
biodegradable polymer with non-toxic degradation products that are easily removed 
from the organism by natural metabolite pathways. Nanoparticulate systems based on 
PLGA have also been the subject of research in the treatment of osteomyelitis. Calcium-
phosphate (CP) is chemically similar to the mineral component of bones and it has the 
capacity to promote and stimulate the regeneration of bone tissue [7-10]. 
Multifunctional nano drug delivery systems (MNDDS) for the controlled drug delivery 
based on calcium phosphates and bioresorbable polymers are the subject of our recent 
research related to bone engineering [7, 8, 11, 12]. The basic idea behind this concept is 
to exhibit the activity of MNNDS through two successive steps. The first step includes 
the controlled release of an antibiotic accompanied with polymer resorption. In the 
second step, CP particles coated with the polymer, which remain in place, act as filler 
for potential damages in bone tissue [7]. Composite biomaterials based on calcium 
phosphates in nanoparticulate form (NPs) compared to micro or submicron particles 
may have several advantages in terms of improving the quality of the treatment [13-15]. 
Different groups of composite biomaterials based on hydroxyapatite nano particles were 
synthesized for the purpose of reconstruction of bone tissue [16, 17]. 
Having in mind that currently used antibiotic therapy options have limited effect on 
antibiotic-resistant bacteria, such as gentamicin-resistant Staphylococcus aureus and 
methicillin-resistant Staphylococcus aureus (MRSA), there is an urgent need for new 
multifunctional antibiotic delivery systems to combat these resistant pathogens [18-21]. 
Tigecycline (TG) is the first in the new class of antimicrobial agents, the glycylcyclines, 
which are structurally derived from the tetracycline nucleus. The antimicrobial activity 
of TG is based on the inhibition of protein synthesis in bacteria, by binding them to the 
30S ribosome subunit, blocking the bond to the tRNA, on the mRNA–ribosome 
complex [22-25]. TG appears to find potential application in the treatment of severe 
orthopedic infections. Several case reports of the treatment of osteomyelitis, caused by 
multi-drug-resistant microbes, with TG have been published so far [26-28]. TG has 
displayed good bone penetration and a broad antimicrobial spectrum, including all the 
pathogens found in nosocomial orthopedic infections including MRSA [21]. 
The purpose of the study presented in this paper has been to examine the effects of 
different concentrations of tigecycline on osteoblast cells and find out the appropriate 
concentration of tigecycline in the multifunctional nano drug delivery system consisting 
of tigecycline-loaded CP/PLGA that can maintain antibacterial properties during 
potential applications in a living tissue. Despite the increasing use of tigecycline and the 
reported high concentrations in bone tissue, there are no data available concerning the 
direct effects of tigecyline on bone cells. The objective of this in vitro study has been to 
determine what dosage of tigecycline causes changes in the morphology of osteoblasts 
and reduces the number of osteoblast cells. We have also examined whether MNDDS 
based on tigecycline-loaded CP/PLGA is compatible and whether it can release 
bioactive TG in a controlled manner within three weeks; after that period, in vitro 
research were carried out. 
 
2. Materials and Methods  
2.1 Preparations of composite biomaterial  
Synthesis of a tigecycline-loaded nano composite biomaterial in which each calcium 
phosphate particle was coated with the bioresorbable poly-DL-lactide-co-glicolide 
polymer, was described early [7]. The calcium phosphate gel was added into completely 
dissolved polymer containing different ratios of Tigecycline (Tygacil/Tigecyclin, Wyeth 
Europe Ltd., Berkshire, SL6 OPH). The suspension was mixed at 18,000 rev/min, and 
then methanol was added. Afterwards, PVA (0.02% in water) was added into the 
suspension (PLGA/PVA = 10/1) [7]. Tigecyclin (T) content in the composite was 
obtained after calculating the encapsulation efficiency (%), according to the 
methodology presented in literature [29]; the encapsulation efficiency in our 
experiments was 70 ± 3%. Nano-sized particles of CP/PLGA (without tigecycline), 
CP/PLGA loaded with 0.6wt% tigecycline (CP/PLGA/TG0.6) and 5wt% tigecycline 
(CP/PLGA/TG5.0) were synthesized. Microstructural characterization was done by 
atomic force microscopy (AFM; Thermo Microscopes, Autoprobe CP Research). The 
samples were sterilized in a 60Co radiation facility, in air at room temperature, at a dose 
rate of 9 kGy/h, to absorbed doses of 25 kGy before use [7]. X-ray (XRD) analyses were 
made using a Bruker D8 advance diffractometer equipped with focusing Ge crystal 
primary monochromator that generates CuK radiation. The chemical composition was 
identified by infrared spectroscopy, performed on a Michelson interferometer with 
duplex mechanical bearings and a linear motor, resolution 32–0.5 cm-1, spectral range 
DTGS 7.8–400 cm-1, and an accuracy lower than 0.01 cm-1. 
 
2.2 Cell Culture  
The mouse osteoblast-like cell line, MC3T3-E1 (DSMZ, ACC210, Braunschweig, 
Germany) was routinely cultured in alpha-MEM (PAA Laboratories Gmbh, Austria) 
supplemented with 10% fetal calf serum (PAA Laboratories Gmbh, Pasching, Austria), 
100 U/ ml penicillin, and 0.1 mg/ ml streptomycin (PAA Laboratories Gmbh) at 37°C in 
humidified atmosphere of 95% air and 5% CO2. The test samples were placed in 24-
well cell culture plate and seeded with 2 x 105 cells in 0.5 ml medium.  
 
2.3 Cytotoxicity  
The cytotoxicity [30] was tested by analyzing the release of lactate dehydrogenase 
(LDH) into the cell culture medium. LDH was measured using the microplate based 
Cytotoxicity Detection Kit (LDH) (Boehringer, Mannheim, Germany). According to the 
manufacturer’s protocol, 50 μl of the cell culture medium was used and absorbance was 
measured at 492 nm using a plate reader (ASYS Hitech GmbH, EXPERT 96, Austria). 
The total protein content was measured using the microplate-based Pierce® BCA 
Protein Assay Kit and the working reagent was prepared according to the 
manufacturer's protocol; an amount of 250 μl of the cell culture medium was used and 
the absorbance was measured at 550 nm using a plate reader (ASYS Hitech GmbH, 
EXPERT 96, Austria). The culture medium without cells was used as a zero absorbance 
reference to calibrate the spectrophotometer. LDH activities were calculated in 
percentage of the LDH activity against the total cell death induced by 1% Triton X-100 
treatments (control).  
 
2.4 Tigecycline treatment 
Tigecycline antibiotic powder (Wyeth, USA) was solubilized following the 
manufacturers’ instructions to obtain six different concentrations (0, 0.5, 5, 50, 250, and 
500 μg/ml). The attachment of cells to the bottom of the culture plates was achieved 
after 24 h. The cells were incubated for another 24, 48 or 72 h before the assessment of 
the cell cytotoxicity and morphology. The cell medium was changed after 24 hours. The 
number of cells was 300,000 or 300,000 per hole in 1 ml. The results were expressed as 
a ratio of released LDH to the amount of untreated control cells.  
 
2.5 CP/PLGA tigecycline treatment 
After 24 h, the attachment of cells was achieved, the medium was removed, and 1 ml of 
fresh medium was added to each well containing 0.02 g pulver of CP/PLGA (without 
tigecycline), CP/PLGA/TG0.6 and CP/PLGA/TG5 [21]. Cells were then incubated for 
another 24, 48, and 72 h before the assessment of the cell cytotoxicity. We attempted to 
describe through quantitative parameters the manner in which extracts from CP/PLGA, 
CP/PLGA/TG0.6 and CP/PLGA/TG5 induce the LDH activity in the extracellular 
space. The medium was changed after 24, 48 and 72h. 
 
2.6 Morphology 
The morphology of the cells cultivated with different concentrations of TG and of those 
from the control (without tigecycline) culture were examined after 24, 48 and 72 hours 
using a light microscope with a 10x and a 40x objective (Olympus 1x70, Hamburg, 
Germany). 
 
2.7 Verification of the microbiological activity of tigecycline-loaded CP/PLGA  
In order to test the antibacterial activity of the released TG from tigecycline-loaded 
CP/PLGA, the growth inhibition of the most common organism causing osteomyelitis, 
S. aureus, was used [20,31]. Staphylococcus aureus ATCC 10832 was inoculated on the 
surface of nutrient agar plates. Six sterile blank 6-mm paper discs were placed on the 
surface of each inoculated agar plate. Each disc was loaded with 50μl of the standard 
TG solutions and incubated for 24 h, after which the diameters of the zones of complete 
inhibition (including the diameter of the disc) were recorded in millimeters. The 
concentrations were then plotted on a semilogarithmic scale versus their corresponding 
zone diameters to give a standard curve. Six-millimeters discs of CP/PLGA, 
CP/PLGA/TG0.6 and CP/PLGA/TG5 were incubated in sterile saline for 24 h, seven, 
14 and 21 days and after that, they were applied in triplicate to the prepared bioassay 
agar plates incubated at 30°C for 24 hours. The diameters of the zones of inhibition for 
the standards and the samples were measured manually. The six measurements per zone 
of inhibition (three measurements per sample × two replicates) were averaged. The 
concentrations of the samples were determined by comparing the mean zone size of the 
samples to the zone sizes of the standard curve and their corresponding concentrations. 
All measurements were documented with photos and performed by a person who was 
not involved in the research. 
 
2.8 Statistical analysis 
The statistical analysis was performed using the software package Sigma Plot version 
11.0. Groups of data were evaluated using a one-way analysis of variance (ANOVA) 
followed by the Kruskal-Wallis tests for all pair wise multiple comparisons or Dunn's 
for multiple comparisons versus the control group. The significance was set at p < 
0.001. The data were presented as the mean ± standard error. All experiments were done 
thrice with a minimum of four samples for each concentration and parameter. 
 
3. Results 
3.1 Tigecycline-loaded calcium phosphate/poly-DL-lactide-co-glycolide basic analysis  
Difraktogram of tigecycline-loaded calcium phosphate/poly-DL-lactide-co-glycolide 
loaded with 5wt% tigecycline (specimens with maximum ratio of TG) is shown in 
Figure 1a. In Figure 1b shows the FT-IR spectrum of the same material. 
The most intense peaks, in Figure 1a, at 31.80 (2 1 1), 32.20 (1 1 2), 32.90 (3 0 0) and 
49.50 (2 1 3) originate from calcium hydroxyapatite (HAp). Peaks at 16.90, 18.20, 23.10 
and 43.00 derived from tigecycline. The FT-IR spectra shown in Figure 1b are observed 
doublets with maxima at 1,035 and 1,092 cm-1, which are the most intense and originate 
from phosphate groups, and by a triplet with maxima at somewhat lower frequencies of 
561 and 603 cm-1, arising from the PO43- group vibrations [7]. The intense, sharp band 
at 1,760 cm-1 is attributed to C=O vibration from PLGA. The band at 1,521 cm-1 
corresponds to the most intense peaks from tigecycline C29H39N5O8.  
The microstructure of CP/PLGA and CP/PLGA/TG composite biomaterial was studied 
by AFM. Fig. 2 shows the morphology of the the CP/PLGA, CP/PLGA/TG0.6 and 
CP/PLGA/TG5 composite biomaterial prepared according to experimental procedures. 
It was established by linear AFM analysis that the average particle diameter of this 
composite varied from 65 to 95 nm. 
Figure 1.  
Figure 2. 
 
3.2 Cell morphology 
A treatment with TG leads to considerable changes in the cell morphology and the cell 
spread on the surface. After 72 hours of incubation, the control osteoblast-like cells 
were uniformly distributed on the culture plate and they exhibited the characteristic 
cuboidal morphology (figure 3a). The cell borders were well defined; the cells were 
attached to the surface and exhibited a spread, flattened shape (figure 3a). We observed 
no changes in the cellular morphology when the osteoblasts were treated with 0.5 
μg/mL, 5 μg/mL and 50 μg/mL TG (figure 3b). At a concentration of 250 μg /mL TG, 
there were fever cells in the focus and the cells became more fibroblast-like with a 
spindle shape and with long processes extending between cells (figure 3c). At 500 μg 
/mL, this tendency was even more pronounced (figure 3d). 
Figure 3.  
 
3.3 Lactate dehydrogenase assay 
All doses of TG greater than 50μg/mL on days 1, 2 and 3 resulted in an increased (p < 
0.001) release of LDH compared to that of the control cells (figure 4). Although the data 
collected on days 1 and 2 showed a similar downward trend when the osteoblasts were 
treated with 0.5 μg/mL, 5 μg/mL TG, there have been no significant differences from 
the controls. As far as the time effect at each concentration of TG is concerned, the 
LDH activity did not significantly change at any concentration of the antibiotic during 
the observation period. 
Compared to the corresponding controls at each time point, CP/PLGA/TG0.6 did not 
reveal cytotoxic effects (figure 5). A significantly decreased LDH activity was observed 
in the CP/PLGA/TG5 incubated for between 24 and 72 h (p < 0.001).  
Figure 4.  
Figure 5.  
3.4 Microbiological activity of the released tigecycline from tigecycline-loaded 
CP/PLGA 
The results of the TG biological activity test are presented as the mean value in table 1. 
CP/PLGA did not exhibit any biological activity. CP/PLGA/TG0.6 and CP/PLGA/TG5 
showed an average zone of inhibition of 19 and 30 mm, respectively. The zones of 
inhibition indicate that biologically active TG is present in the sample. Different 
biological effect of the samples corresponds to different concentrations of the antibiotic. 
The inhibitory activity of the diluents and their effect on the standard curve did not 
allow for the quantification of the amount of TG. 
Table 1.  
4. Discussion 
XRD analysis results indicate the presence of calcium phosphate phases and tigecycline 
in the synthesized powder. Form of XRD peaks in Figure 1a shows the existence of 
poorly crystalline calcium hydroxyapatite. PLGA polymer because of its amorphous 
structure does not show the diffraction peaks. Based on the position and intensity of the 
characteristic peaks of tigecycline (16.9°, 18.2°, 23.1° and 43.0°) it is likely that the 
given phase is tigecycline crystalline form I. There are different crystalline forms of TG 
and the results indicate the existence of consent forms I [32, 33].  
FTIR spectrum is shown in Figure 1b confirmed the existence of HAp, TG and PLGA 
phase in the synthesized powder.  
The AFM image of the composite without tigecycline is shown in Fig. 2a and it 
indicates an average particle diameter of around 65 nm. The AFM morphology of the 
composite containing 0.6% and 5% of tigecycline is shown on Fig. 2b, c. Undoubtedly, 
the increase in the tigecycline content within the composite leads to the increased 
average particle diameter up to 95nm. In accordance with the XRD and FTIR results, 
CP particles coated with tigecycline-loaded PLGA were obtained. In our previous 
studies it was shown that the average particle size ranges of the nano-sized powder 
between 65 and 95 nm [7].  
Although the efficacy of the local antibiotic delivery systems is beyond dispute, the 
effect of high doses of antibiotics on local tissues is not well covered in relevant 
literature. The literature data indicate that increased antibiotic concentrations are 
accompanied with an increase in toxicity, suggesting that higher doses of the antibiotic 
may be better for the control of the infection; however, they are by no means benign 
[34]. It is important to take into consideration that most local delivery systems release a 
very high dose of antibiotics; in some cases the concentration is higher than 1000 times 
the MIC 90 [35-38]. 
To our knowledge, the present study has demonstrated the inhibitory effects of pure TG 
and the TG released from tigecycline-loaded CP/PLGA on osteoblasts in vitro for the 
first time. In the interpretation of our data, we have noted important caveats. First, we 
focused on the cytotoxicity and did not evaluate the cellular function in detail. The full 
bio programme has been beyond the scope of this paper. In addition, we evaluated the 
effect of the antibiotics in an in vitro system and our findings may not be directly 
applicable to an in vivo situation. 
We have shown that the TG treatment at serum and bone concentrations achieved in a 
conventional intravenous antibiotic therapy 0.5 μg/ml – 5 μg/ml neither yields toxic 
effects nor causes morphological change in osteoblasts in vitro [31,37]. A concentration 
of tigecycline one-hundred-fold higher than MIC 50 for coagulase-negative 
staphylococci (CNS) did not cause negative effects on osteoblasts, which indicates that 
tigecycline could be used as a part of MDDS [39]. Higher concentrations, 250 μg/ml 
and above, caused high toxic effect and impaired normal osteoblastic morphology, 
indicating a fibroblastic rather than osteoblastic phenotype, maybe in a sense of 
dedifferentiation. The effect of the concentrations of TG, 500- or 1000-fold higher than 
MIC 50 for CNS, indicates that a MDDS based on TG could be compatible only if it 
had a well controlled antibiotic release rate. The cytotoxic and cytostatic effects of 
tetracycline on osteoblasts could be explained by a mitochondrial energetic impairment. 
Tetracycline is known to inhibit the bacterial protein synthesis, as well as the eukaryotic 
protein synthesis and protein synthesis of isolated mitochondria [37, 40-42]. Significant 
morphological changes of cells in spread, cell membrane, and extensions were also 
detected with the use of other antibiotics (ciprofloxacin, vancomycin) over the dose 100 
μg/ml [43]. 
We have demonstrated that there was no impact on the percentage of viable osteoblasts 
incubated with CP/PLGA in the first 24 h, which is in accordance with our earlier 
research [44]. Low cytotoxicity values are probably the consequence of high 
compatibility of both constituents of the biocomposite material. The investigation of the 
time effect on each sample showed that the extracts from CP/PLGA increased 
significantly the LDH activity at each time point, but this activity was no more than two 
folds higher than that of the controls. Faster degrading polymers, like low–molecular-
weight PLGA or PLA, can give rise to a cytotoxic reaction due to the production of 
acidic degradation products [45-47]. 
Compared to the corresponding controls at each time point, CP/PLGA/TG0.6 did not 
reveal cytotoxic effects. During the first day, eight percent of the total TG was released, 
calculated 9.6 µg of TG; [7] this concentration of TG did not cause cytotoxic effects. 
The lower LDH activity in the cells incubated with CP/PLGA/TG0.6 than that in the 
cells incubated with CP/PLGA can be explained by a positive proliferation effect of 
tetracycline on osteoblasts [40]. The mechanisms underlying the effects of tetracyclines 
on osteoblastic cells remain unclear. However, tetracyclines can inhibit collagenase 
and/or the breakdown of collagen under a variety of conditions. These events might 
result in improved osteoblastic behaviour, having in mind that a stable collagenous 
matrix is known to play a significant role in the osteoblastic proliferation/differentiation 
sequence [48-50]. CP/PLGA/TG5 significantly decreased the LDH activity from 24 to 
72 h. This can be explained by the high TG release in the first day and its deleterious 
effect on osteoblasts. During the first day, 20% of the total TG was released – namely, 
200µg of TG. The highest release rate during the first day is related to the fact that a 
great amount of the antibiotic is adsorbed on the surface of nanoparticles, which is the 
consequence of the synthesis procedure. The zones of inhibition around the samples 
indicate that biologically active TG remains in the sample for three weeks. The 
quantification and the release mechanism of TG from implants in vivo and in vitro, 
important for potential preclinical applications, were dealt with in our previous study 
[7]. 
 
5. Conclusions 
Multifunctional nano drug delivery systems (MNDDS) based on tigecycline-loaded 
calcium phosphate/poly-DL-lactide-co-glicolide have shown good compatibility and 
antibacterial effect during the observation time and thus appear to be a suitable drug 
delivery system for the treatment of osteomyelitis caused by multidrug-resistant 
microbes. Tigecycline-loaded calcium phosphate/poly-DL-lactide-co-glycolide with 
0.6wt% of tigecycline shows a low level of the cytotoxic and LDH activity.   
This study provides additional rationale for an improved patient dosing and the 
necessity for a balance between the antibacterial and biocompatible properties of 
multifunctional local delivery systems. Tigecycline treatment at concentrations achieved 
in a conventional intravenous antibiotic therapy did not yield toxic effects or caused 
morphological changes of osteoblasts in vitro. However, at high concentrations as 
achieved by local application, tigecycline caused high toxic effect and impaired normal 
osteoblastic morphology; therefore it may be detrimental for bone healing and repair in 
vivo.  
Further in vitro studies should highlight the effects of tigecycline on the metabolic 
activity, extracellular matrix calcification and differentiation of human osteoblasts. 
Additional in vivo studies should focus on a prolonged effect of high tigecycline levels 
on bone healing and implant incorporation. 
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 Figure and table caption 
 
Figure 1. Tigecycline-loaded calcium phosphate/poly-DL-lactide-co-glycolide (a) XRD 
diffraction (b) FT-IR spectra. 
Figure 2. AFM image of (a) CP/PLGA), (b) CP/PLGA/T0.6, (c) CP/PLGA/T5.0. 
Figure 3. MC3T3-E1 osteoblast-like cell cultures incubated with (a) 0, (b) 50 μg/mL, 
(c) 250 μg/mL, (d) 500 μg/mL TG in alpha-MEM medium for 72 hours, visualized by 
light microscope with original magnification ×40.  
Figure 4. Specific LDH activity after one, two and three days in the medium with cell 
line MC3T3 incubated with different concentrations of TG 0-500 μg/mL.  
Figure 5. Specific LDH activity after one, two and three days in the medium with cell 
line MC3T3 incubated with CP/PLGA, CP/PLGA/TG0.6 and CP/PLGA/TG5.0. 
Table 1. The zone of inhibition around CP/PLGA, CP/PLGA/TG0.6 and 
CP/PLGA/TG5.0 determined by the microbiological assay using S. aureus. The values 
are presented as the mean value of a triplicate. 
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Figure 1a.  
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Figure 1b.  
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Figure 5.  
 
 
 
 
 
Table 1.  
inhibition zone 
[mm] 
incubation 
time [days] 
CP/PLGA CP/PLGA/T0.6 CP/PLGA/T5.0 
1 0 19 30 
7 0 21 30 
14 0 20 25 
21 0 19 22 
 
 
 
 
 
 
 
